Vyasa Analytics provides a highly scalable deep learning platform for organizational data, enabling conceptual querying and collaborative analytics to help inform key decisions derived from your most valuable information assets.
Vyasa Analytics provides deep learning software and analytics for life sciences and healthcare organizations
Dr. Christopher Bouton earned his Ph.D. in molecular neurobiology from Johns Hopkins University and sold his first big data software company, Entagen, to Thompson Reuters in 2013. Living in India for four years as a boy, he developed a great respect for Vyasa – an important Hindu figure, storyteller and compiler of information – and believes that AI approaches will help us better compile and gain insights from our data systems. In 2016, he founded Vyasa Analytics to apply AI in life sciences and healthcare.
Vyasa engages with life sciences and healthcare organizations to educate the industry about deep learning technologies, including speaking alongside executives at conferences and events. Dr. Bouton is also a frequent contributor and commentator to industry publications.
In 2016, the pharmaceutical industry spent some $157 billion on research and development. This figure is set to increase to more than $180 billion by 2022. The healthcare analytics market was $8.69 billion by 2016 and is estimated to reach $33.38 billion by 2022.
Vyasa is positioned to capture hundreds of millions of dollars in these markets by allowing organizations to conduct analytics on data relevant to their research. Other analytics companies in the space experiencing rapid growth include Lattice.io (acquired by Apple for $200 million), BenevolentAI (valued at $1.7 billion) and Exscientia (recent deals with GSK for $43 million and Sanofi for $273 million).
Who are your competitors?
While there are many deep learning companies, Vyasa is the only one applying deep learning to life sciences and healthcare specifically.
How your company differentiates itself from the competition?
Focusing in the life sciences and healthcare verticals is a key differentiator for Vyasa. In partnership with life sciences and healthcare organizations, we build software to help design better therapeutics, free up researchers for higher-level thinking and solve problems that matter for humanity.
Vyasa has a B2B business model. Every project is a blend of software licensing and services, provided to the life sciences or healthcare organization to advance their research goals. We are projecting upwards of $3 million in revenue in 2018.